# A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

> **NCT03430063** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Advanced Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** SDREGN2810
- **DRUG:** SDREGN2810/ipi
- **DRUG:** HDREGN2810

## Key facts

- **NCT ID:** NCT03430063
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-29
- **Primary completion:** 2021-10-27
- **Final completion:** 2021-10-27
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430063, "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03430063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*